Mao Zhifang, Hu Meng, Shen Qinglin
Department of Oncology, Jiangxi Provincial People's Hospital, the First Affiliated Hospital of Nanchang Medical College, Nanchang, China.
Institute of Clinical Medicine, Jiangxi Provincial People's Hospital, the First Affiliated Hospital of Nanchang Medical College, Nanchang, China.
Front Bioeng Biotechnol. 2024 Aug 30;12:1443843. doi: 10.3389/fbioe.2024.1443843. eCollection 2024.
Epithelial cell adhesion molecule negative circulating tumor cells (EpCAM- CTCs) and EpCAM positive CTCs (EpCAM + CTCs) have different biological characteristics. Therefore, the isolation of EpCAM + CTCs and EpCAM- CTCs is a new strategy to study the heterogeneity of tumor cells. The azobenzene group (Azo) and cyclodextrin (CD) composite system forms a photosensitive molecular switch based on the effect of external light stimulation. We used the technology of specifically capturing CTCs using anti-EpCAM and aptamers functionalized nanochips. Both anti-EpCAM and aptamers can be connected to Azo through the 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide/N-hydroxysuccinimide (EDC/NHS) modification process. Therefore, we assume that a photosensitive intelligent nanoreactor (PSINR) modified with anti-EpCAM can be used to capture EpCAM + CTCs; Utilizing the characteristics of aptamer and ligand binding, a PSINR modified with aptamer is used to capture EpCAM- CTCs; Then, two PSINRs were separated and stimulated with light to release EpCAM + CTCs and EpCAM- CTCs, respectively. Based on the isolation the EpCAM + CTCs and EpCAM- CTCs, we expected to reveal the key biological mechanisms of tumor recurrence, metastasis and drug resistance, and make the individualized treatment of liver cancer more targeted, safe and effective, and provide a new basis for the final realization of accurate and individualized treatment of tumors.
上皮细胞粘附分子阴性循环肿瘤细胞(EpCAM- CTCs)和EpCAM阳性循环肿瘤细胞(EpCAM + CTCs)具有不同的生物学特性。因此,分离EpCAM + CTCs和EpCAM- CTCs是研究肿瘤细胞异质性的一种新策略。偶氮苯基团(Azo)和环糊精(CD)复合体系基于外部光刺激作用形成一种光敏分子开关。我们利用抗EpCAM和适配体功能化纳米芯片特异性捕获CTCs的技术。抗EpCAM和适配体均可通过1-乙基-3-(3-二甲基氨基丙基)碳二亚胺/ N-羟基琥珀酰亚胺(EDC / NHS)修饰过程连接到Azo上。因此,我们假设用抗EpCAM修饰的光敏智能纳米反应器(PSINR)可用于捕获EpCAM + CTCs;利用适配体与配体结合的特性,用适配体修饰的PSINR捕获EpCAM- CTCs;然后,将两种PSINR分离并分别用光刺激以释放EpCAM + CTCs和EpCAM- CTCs。基于对EpCAM + CTCs和EpCAM- CTCs的分离,我们期望揭示肿瘤复发、转移和耐药的关键生物学机制,并使肝癌的个体化治疗更具针对性、安全性和有效性,为最终实现肿瘤的精准个体化治疗提供新依据。